ad image
INTERPHEX Postponed Due to COVID-19

INTERPHEX Postponed Due to COVID-19

Mar 10, 2020PR-M03-20-NI-012

NEW YORK, NY - International Pharmaceutical Expo (INTERPHEX), the premier event dedicated to pharmaceutical and biotechnology innovation, technology and knowledge from development through commercialization, will be postponed due to the COVID-19 virus. INTERPHEX 2020, scheduled for April 28th through 30th at the Javits Center in New York City, will now take place later this year in New York.

 

“We want to express our concern for those impacted by COVID-19,” said Randy Field, Group Vice President, Reed Exhibitions. “We have been closely monitoring developments and reviewing guidance related to the COVID-19 virus from federal, state and local authorities and public health officials, including the United States Centers for Disease Control (CDC) and the World Health Organization (WHO). While we recognize and appreciate how important INTERPHEX is to the industry, we also are aware that this is a global industry and many of our customers are faced with travel restrictions. More importantly, the INTERPHEX community is uniquely equipped to support authorities and have a positive impact on addressing the COVID-19 virus. Therefore, we have made the decision to postpone INTERPHEX 2020 to dates that will enable the industry to regroup, reflect and get back to business.”

 

INTERPHEX’s mission is to be the event where industry professionals and leading suppliers come together to find solutions to develop and manufacture cost-effective, quality therapeutics for the global population. The INTERPHEX team is determining new dates for INTERPHEX 2020 and will make an announcement shortly.

“First and foremost, it is our responsibility to prioritize the health and safety of our attendees, exhibitors, association and publication partners and staff,” said Kate Scott, Event Director, INTERPHEX. “While we recognize the challenges and inconvenience the postponement causes, we believe this is the right decision for our customers and the industry in general, which is a vital part of getting the pharmaceutical supply chain back on track post-outbreak.”